Clear your blood. Reclaim your heart.
Antonio Colmenares
CEO, Black Forest Supplements
By Antonio Colmenares
99 out of 99 cardiac patients had microclots, the clinical term for silent vessel buildup, circulating in their blood. The standard cardiac toolkit your doctor was handed doesn’t test for it. Doesn’t treat it. Doesn’t even acknowledge it. Today, we’re changing that.
About 700,000 Americans died of cardiovascular disease last year.
If American cardiovascular mortality were running at Japan’s rate, roughly 350,000 fewer Americans would have died. Same wealth. Same hospital infrastructure. Half the death rate.
The cardiologists who built that lower floor have known about this silent buildup for forty-six years. American cardiology still doesn’t put it on a lab requisition form.
Microclots, as the clinical literature calls them, are tiny, sticky knots of fibrin: the protein your body uses to seal a wound. In simpler terms, silent vessel buildup.
Normally, that protein gets broken down and cleared once the wound has healed. In millions of Americans, it doesn’t:
A 2022 peer-reviewed study tested 99 cardiac patients for this kind of fibrin accumulation. They found it in all 99 (Pretorius et al., Cardiovascular Diabetology, 2022).
Your doctor isn’t the problem. The toolkit they were handed is. The American cardiovascular drug-and-procedure economy clears $400 billion a year. Patients with clean vessels don’t move that number. So nothing in the standard kit addresses what is already built up inside your arteries.
This is not a failure of medicine. It is a failure of incentive.
Picture the smallest blood vessels in your body. The capillaries running through your heart, your brain, your kidneys, your fingertips. They are narrower than a single red blood cell, which has to bend single-file to get through.
Now picture a knot of sticky fibrin (the protein your body uses to seal a wound, accumulating where it should not) the size of three red blood cells, slowly building up in those same vessels. The clinical literature calls it a microclot. In your body, it does not announce itself. It just gets stuck. Then another one gets stuck behind it. Then a third. The cells downstream stop getting fed. The tissue downstream starts to fail, quietly, organ by organ, year by year.
By the time it shows up on a scan, the damage has been compounding for a decade.
The science is not ambiguous. The treatment gap is.
More than 80 million Americans are on at least one standard cardiac drug. Roughly 40 million on a statin. 30 million on a daily antiplatelet like low-dose aspirin. 7 million on a long-term blood thinner. Not one of those drugs addresses the silent vessel buildup already accumulated in their arteries.
Mechanism by mechanism:
Every approved drug in the cardiac category is built around prevention. None is built around clearance of what has already accumulated.
Why? Because the molecules that do break down fibrin in the body are natural enzymes. No patent. No trial funding. The industry doesn’t invest in what it can’t own.
Citations: Pretorius et al., Cardiovascular Diabetology, 2022. Chen et al., Frontiers in Cardiovascular Medicine, 2022. Nissen et al., ASTEROID, JAMA, 2006.
Today we introduce the most advanced 4-stage enzyme stack we have ever built: the Black Forest 4-in-1 Nattokinase 10,800 FU Complex.
Four clinically-dosed enzymes:
in one enteric-coated, soy-free capsule. One daily with your largest meal.
We built it because no one else would.
Nattokinase is an enzyme isolated from nattō, the traditional Japanese fermented soybean dish, in 1980. It was the first dietary enzyme researched for activity on fibrin (the protein scaffold that builds up in vessels), studied for its support of the body’s own clearing system.
Nattokinase is researched for its activity on fibrin and is studied for its support of the body’s natural fibrin-clearing pathway.
Most nattokinase on the shelf clocks in at 2,000 FU per capsule, the bare minimum to print the word on a label. 10,800 FU per capsule is more than five times the typical drugstore dose, at the high end of clinically studied dosing.
Ours is fermented on a soy-free Bacillus subtilis substrate (rare in nattokinase). Matters for soy sensitivity, autoimmune concerns, or a soy-free preference.
The coating gets the enzyme past stomach acid into the small intestine intact.
Serrapeptase was isolated from the gut of the silkworm, the same enzyme the moth uses to dissolve its cocoon and emerge.
Serrapeptase is a protein-digesting enzyme. It digests fibrin and the leftover protein debris and dead-cell fragments that nattokinase leaves behind.
Nattokinase supports clearance of the fibrin mesh. Serrapeptase supports clearance of the debris. Without it, lingering debris re-triggers fresh fibrin accumulation downstream.
SPU stands for Serrapeptase Units. Clinical thresholds for whole-body activity start around 40,000 SPU. At 180,000, the dose is built for full whole-body support, not just localized inflammation.
Lumbrokinase is an earthworm-derived enzyme used in traditional Asian medicine for centuries.
Where nattokinase handles fresh fibrin, lumbrokinase is researched for aged fibrin: the hardened, knotted buildup that has been accumulating for months or even years and resists nattokinase entirely.
Adults with years of silent vessel buildup don’t just need help slowing new accumulation. They need an enzyme that can support breakdown of what has already aged in the vessels. Lumbrokinase is the only oral enzyme research has shown to do that. It is also the enzyme most other formulas leave out, because it is expensive, hard to source, and hard to verify.
Calcium ends up where you don’t want it if you don’t tell it where to go.
Vitamin K2 (MK-7) activates the protein that routes calcium away from artery walls toward bones, where it belongs. Arterial calcification (the calcium buildup that hardens artery walls) traps fibrin and accelerates artery decline. Supporting breakdown of the fibrin mesh without addressing the calcium leaves vessels still vulnerable. K2 closes that loop.
MK-7’s half-life is 72 hours; MK-4’s is one hour. One daily MK-7 dose covers a full day.
180 mcg is the dose used in the Knapen MK-7 arterial-stiffness trial, at the upper end of clinical dosing.
You swallow it with your largest meal. The enteric coating gets the four enzymes past your stomach acid and into your small intestine, where they’re absorbed into your bloodstream over the next 60 to 90 minutes.
Then they go to work in sequence.
First, nattokinase reaches the fresh fibrin buildup. Wherever the most recent fibrin scaffolding is accumulating, even a small patch you didn’t know was forming, nattokinase is researched for its activity on it. Like fraying a fishing net into rope, then into thread, then into nothing.
Then serrapeptase supports cleanup of what nattokinase leaves behind. Broken fibrin still triggers inflammation. Inflammation tells your body to lay down more fibrin. Serrapeptase supports digestion of the debris so the inflammation signal can quiet. Cleanup crew, not breaking crew.
Then lumbrokinase reaches what nattokinase can’t. The old, hardened, knotted fibrin buildup that has been accumulating for months or years. Nattokinase bounces off it. Lumbrokinase is researched for its activity on aged fibrin material, the kind that has aged past the point where nattokinase still acts.
And K2 routes the freed calcium to your bones. As old fibrin is broken down, the calcium that hardened around it is released. If that calcium ends up back in your artery walls, you have traded one problem for another. K2 activates the protein that directs that freed calcium to bone, where calcium belongs.
Four enzymes. Four jobs. One sequence. Take any one of them out and the sequence breaks. That is why this combination, in this order, at these doses.
Engineered around the way fibrin actually accumulates in the body: fresh, inflamed, aged, and trapped.
Build, Materials & Verification:
What is on the label is what is in the bottle. Lot-level Certificate of Analysis on request. 60-day full refund if the molecule does not agree with you. No return required.
Conventional cardiology had 46 years to build a tool that clears what’s already in your blood. They didn’t.
So we did.
It is the first 4-stage enzyme stack at this dose ever assembled. And we built it for your heart.
The silent vessel buildup the standard cardiac toolkit doesn’t address is what this stack was designed for. One capsule a day. Every day. For life.
The 80 million Americans on the standard cardiac drug toolkit won’t read this. Their doctors won’t tell them. Their insurance won’t cover it.
You read this. Your body isn’t going to do it alone.
The first production run is limited.
We built it to clinical-grade standards: lab-verified per batch, Certificate of Analysis available on request, no shortcuts. The lumbrokinase alone, the enzyme every other formula leaves out, is expensive, hard to source, and hard to verify. We are not making this in volumes our existing supply chain can run on thin margin.
There are not many bottles in the first run.
Founding-batch pricing locks for 48 hours before public sale opens.